CUMBERLAND PHARMACEUTICALS INC 8-K

What Happened

• Cumberland Pharmaceuticals Inc. (CPIX) filed an 8-K on July 1, 2026 reporting that it closed the previously announced sale of certain assets to Nuvo Pharmaceuticals (Ireland) DAC and affiliates of Apotex for $100.0 million in cash. The transaction had been approved by shareholders on June 24, 2026. The company also furnished unaudited pro forma financial statements reflecting the Transaction (as of March 31, 2026 and for selected periods).

Key Details

• $100.0 million: aggregate cash consideration received by Cumberland upon closing of the Asset Purchase Agreement (Closing Date).
• ~$5.3 million: outstanding balance under the Pinnacle Bank revolving credit facility that was repaid in full and terminated on June 29, 2026; all related liens and security interests were released.
• July 1, 2026: Cumberland and Nuvo executed Amendment No. 1 to the Asset Purchase Agreement to exclude certain contracts from the assets being transferred.
• Personnel changes: Chris T. Bitterman (VP Sales & Marketing) and James L. Herman (VP Trade & Distribution & Corporate Compliance Officer) will resign effective July 31, 2026 and have accepted offers to join an affiliate of Apotex (offer letters signed July 1, 2026).
• The company issued a press release announcing closing and included forward‑looking statement disclosures and unaudited pro forma financials as exhibits to the 8‑K.

Why It Matters

• The $100M cash proceeds materially change Cumberland’s capital position and liquidity profile; the immediate repayment of the ~$5.3M bank loan eliminates that leverage and related liens.
• Management and staffing changes tied to the transferred assets (two senior VPs moving to an Apotex affiliate) could affect Cumberland’s remaining commercial operations.
• The pro forma financials are preliminary and illustrative; the company warns final accounting adjustments and transaction-related costs may differ from those pro forma figures. Investors should review the company’s 8‑K exhibits and subsequent filings for detailed financial impacts and updates.